Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan effect on plasma adiponectin in end-stage renal disease
IRCT2013112515535N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of losartan in end-stage kidney disease (ESKD), sponsored by Shahrekord University of Medical Sciences. Primary endpoint: plasma adiponectin. Started Jan 2014; status: completed.
02
Drugs
losartan
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT2013112515535N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013112515535N1.